Management of Diarrhea in Patients with HER2-Positive Breast Cancer Treated with Neratinib: A Case Series and Summary of the Literature

INTRODUCTION: Neratinib and neratinib-based combinations have demonstrated efficacy for treatment of human epidermal growth factor receptor 2–positive (HER2+) early-stage and metastatic breast cancers. However, diarrhea has been reported as a common adverse event leading to neratinib discontinuation...

Descripción completa

Detalles Bibliográficos
Autores principales: Kruse, Megan L., Kang, Irene M., Bagegni, Nusayba A., Howell, W. Todd, Moore, Halle C. F., Bedell, Cynthia H., Stokoe, Christopher T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Case Series
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8605449/
https://www.ncbi.nlm.nih.gov/pubmed/34800263
http://dx.doi.org/10.1007/s40487-021-00178-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8605449/
https://www.ncbi.nlm.nih.gov/pubmed/34800263
http://dx.doi.org/10.1007/s40487-021-00178-w

Ejemplares similares